IFIH1 and clinically amyopathic dermatomyositis: A former Japanese study observed that in their anti-MDA5 Ab+ DM/CADM cohort, all of the deaths occurred within the first 6 months of DM/CADM diagnosis and none of the survivors suffered relapsing of RP-ILD (3).